title: Integrated patient and tumor genetic testing for individualized cancer therapy.
abstract: Tumor genome analysis is transforming cancer treatment by enabling identification of specific oncogenic drivers and selection of effective targeted agents. Meanwhile, patient genome analysis is being employed across therapeutic areas to inform selection of appropriate drugs and doses for treatment safety. Integration of patient genome analysis concurrent with preemptive tumor genetic testing will enable oncologists to make informed treatment decisions to select the right dose of the right drug for each patient and their tumor.
authors.affiliation: Department of Clinical Pharmacy, University of Michigan College of Pharmacy, University of Michigan, Ann Arbor, Michigan, USA.
authors.forename: D L
authors.initials: DL
authors.lastname: Hertz
authors.affiliation: DeBartolo Family Personalized Medicine Institute, Division of Population Sciences, Moffitt Cancer Center, Tampa, Florida, USA.
authors.forename: H L
authors.initials: HL
authors.lastname: McLeod
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D005820:Genetic Testing / Q000639:trends*; D016678:Genome; D006801:Humans; D008495:Medical Oncology / Q000592:standards / Q000639:trends*; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy*; D057285:Precision Medicine / Q000592:standards / Q000639:trends*
chemical_list: D000970:Antineoplastic Agents